The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 177-182

  Dinmohamed, Avinash G ^a   van Norden, Yvette ^a   Visser, Otto ^b   Posthuma, Eduardus F M ^c   Huijgens, Peter C ^d   Sonneveld, Pieter ^a   van de Loosdrecht, Arjan A ^d   Jongen Lavrencic, Mojca ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b Department of Cancer Registry and Research   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic myelomonocytic leukemia; Incidence; Medical claims; Myelodysplastic syndromes; Population based; Treatment

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGISTRY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ASSESSMENT; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; NETHERLANDS; POPULATION RESEARCH; SEX DIFFERENCE; VERY ELDERLY; ADOLESCENT; BONE MARROW; INCIDENCE; INSURANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MYELODYSPLASTIC SYNDROMES; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NETHERLANDS;

EID: 84921433666     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.025     Document Type: Article

References (33)

1. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
2. Itzykson R., Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 2013, 27:1441-1450.
3. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
4. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
5. Sant M., Allemani C., Tereanu C., De Angelis R., Capocaccia R., Visser O., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
6. Visser O., Trama A., Maynadie M., Stiller C., Marcos-Gragera R., De Angelis R., et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012, 48:3257-3266.
7. Dinmohamed A.G., Visser O., van Norden Y., Huijgens P.C., Sonneveld P., van de Loosdrecht A.A., et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer 2014, 50:1004-1012.
8. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
9. Greenberg P.L., Attar E., Bennett J.M., Bloomfield C.D., De Castro C.M., Deeg H.J., et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011, 9:30-56.
10. Malcovati L., Hellstrom-Lindberg E., Bowen D., Ades L., Cermak J., Del Canizo C., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013, 122:2943-2964.
11. Onida F., Barosi G., Leone G., Malcovati L., Morra E., Santini V., et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica 2013, 98:1344-1352.
12. Craig B.M., Rollison D.E., List A.F., Cogle C.R. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomarkers Prev 2012, 21:474-481.
13. Goldberg S.L., Chen E., Corral M., Guo A., Mody-Patel N., Pecora A.L., et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010, 28:2847-2852.
14. Cogle C.R., Craig B.M., Rollison D.E., List A.F. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011, 117:7121-7125.
15. McQuilten Z.K., Polizzotto M.N., Wood E.M., Sundararajan V. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. Transfusion 2013, 53:1714-1721.
16. McQuilten Z.K., Wood E.M., Polizzotto M.N., Campbell L.J., Wall M., Curtis D.J., et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 2014, 120:1686-1694.
17. World Health Organization. International statistical classification of disease and related health problems Tenth Revision (ICD-10) 1992, World Health Organization, Geneva.
18. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, IARC, Lyon.
19. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon.
20. Comprehensive Cancer Centre Netherlands The Netherlands cancer registry 2014, Comprehensive Cancer Centre Netherlands.
21. Ma X, Wang R. Ascertainment of patients with myelodysplastic syndromes. J Clin Oncol 2011, 29:e16. (author reply e17).
22. Smith A., Howell D., Patmore R., Jack A., Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011, 105:1684-1692.
23. Maynadie M., Girodon F., Manivet-Janoray I., Mounier M., Mugneret F., Bailly F., et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica 2011, 96:55-61.
24. Neukirchen J., Schoonen W.M., Strupp C., Gattermann N., Aul C., Haas R., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 2011, 35:1591-1596.
25. Osca-Gelis G., Puig-Vives M., Saez M., Gallardo D., Sole F., Marcos-Gragera R. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007. Leuk Res 2012, 36:1262-1266.
26. Steensma D.P. Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep 2012, 7:310-320.
27. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., Woodman R.C. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263-2268.
28. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
29. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
30. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
31. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
32. Such E., Germing U., Malcovati L, Cervera J., Kuendgen A., Della Porta M.G., et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013, 121:3005-3015.
33. Itzykson R., Kosmider O., Renneville A., Gelsi-Boyer V., Meggendorfer M., Morabito M., et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013, 31:2428-2436.